# About Peptide GHK-Cu > About Peptide GHK-Cu: A Readout Over the Copper Tripeptide Literature — Peptide GHK-Cu is a readout panel over the published GHK-Cu literature — figures pinned to the studies that produced them. Not a clinic, not a supplier, nothing prescribed and nothing sold. **COLOPHON // WHAT THIS IS** An instrument reading of one compound's literature: what was measured, in what model, at what tier of evidence. ## What this panel is Peptide GHK-Cu is a readout panel over one compound's published literature. It takes the peer-reviewed record on GHK-Cu — the copper tripeptide, INCI name Copper Tripeptide-1 — and displays it the way an instrument displays a measurement: the figure, the model it came from, and the tier of evidence it sits on, with nothing interpolated between them. No clinic, pharmacy or telehealth service stands behind this panel. Nobody here sees patients, writes a prescription, or hands anything across a counter, and there is nothing on this site to buy, order or request. It supplies, sources and dispenses nothing. It diagnoses nothing and treats nothing. The domain name is the bare category word and the bare compound string — peptide, ghkcu — and that is deliberate. There is no doctor in the name, no clinic and no shop, because the panel occupies none of those positions. It occupies one position only: reading the literature and reporting what it says. ## How the readout is built Every quantitative statement on this site — every concentration, percentage, hair count, gene figure, permeability coefficient and animal dose — carries a numbered marker that resolves on the [GHK-Cu study index](/references) to a specific paper. If a figure has no source, it does not go on the panel. Evidence tier is treated as data, not decoration. A result from a peer-reviewed randomised trial and a result from a preprint are not displayed as the same thing, and this compound makes that distinction unavoidable: the neuroprotection line that gives this digest its angle rests on two 2023 bioRxiv preprints, which are named as preprints wherever they appear. In vitro is called in vitro. Rodent is called rodent. A theoretical caution is labelled theoretical. Community-reported experience is kept on its own page and under its own label, because a forum impression and a placebo-controlled endpoint are different measurements and blending them produces a false reading. Gaps are displayed as prominently as findings. There is no validated human pharmacokinetic data for GHK-Cu, no human neurological trial, and no approved therapeutic indication by any route in any jurisdiction. Those absences are stated on the pages where a reader would otherwise assume otherwise. ## What the panel will not display No human dose, schedule, titration or route recommendation appears anywhere on this site, including in the plain-English sections and including in answers to direct questions about timing and strength. Study parameters are logged on [GHK-Cu research doses by model](/dosage) as what researchers administered to cells and animals, which is a record and not an instruction. No product, brand, vendor, price or place to obtain anything is named. No claim is made stronger than its source supports, and where a widely repeated figure overstates its paper — the "~4,000 genes" extrapolation is the standing example — the panel says so rather than passing it along. The writing is commentary on published science. It is not medical advice, and it is not a substitute for a qualified professional who can weigh an individual's circumstances. --- A readout panel over the GHK-Cu literature: every figure pinned to the study that measured it, every preprint marked as one, and nothing here dosed, diagnosed, prescribed or sold.